TXG 10x Genomics, Inc.
Healthcare$23.68-4.05%ClosedMarket Cap: $3.01B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
3.73
P/S
4.71
EV/EBITDA
-441.21
DCF Value
$-12.96
FCF Yield
4.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.6%
Operating Margin
-6.1%
Net Margin
-3.5%
ROE
-2.9%
ROA
-2.2%
ROIC
-4.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $150.8M | 70.4% | $-17.0M | $-13.5M | $— | — |
| Q4 null | $166.0M | 68.1% | $-19.5M | $-16.3M | $— | — |
| FY null | $642.8M | 69.1% | $-110.9M | $-43.5M | $— | — |
| Q3 null | $149.0M | 67.3% | $-32.2M | $-27.5M | $— | — |
| Q2 null | $172.9M | 72.3% | $30.1M | $34.5M | $— | — |
| Q1 null | $154.9M | 68.1% | $-39.3M | $-34.4M | $— | — |
| Q4 null | $165.0M | 67.2% | $-49.8M | $-49.0M | $— | — |
| FY null | $610.8M | 67.9% | $-194.6M | $-182.6M | $— | — |
| Q3 null | $151.7M | 70.2% | $-41.5M | $-35.8M | $— | — |
| Q2 null | $153.1M | 68.1% | $-41.7M | $-37.9M | $— | — |
| Q1 null | $141.0M | 65.9% | $-61.5M | $-59.9M | $— | — |
| Q4 2023 | $184.0M | 62.9% | $-55.2M | $-49.0M | $-0.41 | — |